BF Biosciences Limited (PSX:BFBIO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
138.54
-1.64 (-1.17%)
At close: Mar 11, 2026
Market Cap12.24B -29.3%
Revenue (ttm)8.22B +82.0%
Net Income598.64M +39.9%
EPS6.78 +8.5%
Shares Out88.33M
PE Ratio20.43
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume129,068
Average Volume282,021
Open140.20
Previous Close140.18
Day's Range138.00 - 141.00
52-Week Range117.00 - 194.90
Betan/a
RSI39.72
Earnings DateFeb 25, 2026

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoul... [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 535
Stock Exchange Pakistan Stock Exchange
Ticker Symbol BFBIO
Full Company Profile

Financial Performance

In fiscal year 2025, BF Biosciences's revenue was 5.84 billion, an increase of 59.55% compared to the previous year's 3.66 billion. Earnings were 447.15 million, an increase of 16.02%.

Financial Statements